SCHEMBL12747762

SCHEMBL12747762

[Rh]c1cccc2cncnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.47
TRPV1 Q8NER1 2/20 0.37
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
MMP2 P08253 1/20 0.32
CHRM1 P11229 1/20 0.32
TSHR P16473 1/20 0.32
COMT P21964 1/20 0.32
ADRA1A P35348 1/20 0.32
METAP2 P50579 1/20 0.32
METAP1 P53582 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
KDM4E B2RXH2 6/20 0.32
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
MAPKAPK2 P49137 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276426 0.79 METAP2 (0.55) EGFRTRPV1MMP2CHRM1TSHR
SCHEMBL276425 0.79 EGFR (0.47) EGFRTRPV1PIK3CDPIK3CAKDM4E
SCHEMBL3074807 0.78 EGFR (0.50) EGFRTRPV1PIK3CDPIK3CAMMP2
Hydrochloric Acid SCHEMBL28754132 0.78 METAP2 (0.53) EGFRTRPV1MMP2CHRM1TSHR
SCHEMBL559673 0.77 EGFR (0.48) EGFRTRPV1PIK3CDPIK3CAKDM4E
SCHEMBL2008880 0.75 EGFR (0.47) EGFRTRPV1PIK3CDPIK3CAKDM4E
SCHEMBL13857915 0.75 PSMD14 (0.55) EGFRTRPV1PIK3CDPIK3CAKDM4E
SCHEMBL2008884 0.75 CYP3A4 (0.47) EGFRTRPV1PIK3CDPIK3CATSHR
SCHEMBL10765869 0.75 EGFR (0.47) EGFRTRPV1PIK3CDPIK3CALMNA
SCHEMBL7989490 0.75 EGFR (0.47) EGFRTRPV1PIK3CDPIK3CATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 US disclosed
US-20240226098-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-07-11 US disclosed
EP-4328230-A2 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2024-02-28 EP disclosed
EP-3889145-B1 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2024-02-21 EP disclosed
EP-3761980-B1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2023-11-29 EP disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 US disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US disclosed
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US disclosed
WO-2008082484-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2008-07-10 WO disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 EGFR 3354/4885TRPV1 4504/4885PIK3CD 2693/4885
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 EGFR 1287/4885TRPV1 737/4885PIK3CD 2707/4885
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 EGFR 4744/4885TRPV1 2912/4885PIK3CD 301/4885
US-20240226098-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 EGFR 4868/4885TRPV1 4437/4885PIK3CD 3109/4885
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L EGFR 2897/4885TRPV1 3566/4885PIK3CD 2546/4885
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 EGFR 4841/4885TRPV1 345/4885PIK3CD 3328/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 EGFR 1287/4885TRPV1 737/4885PIK3CD 2707/4885
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C EGFR 1800/4885TRPV1 3377/4885PIK3CD 4780/4885
US-20070203209-A1 Useful indole compounds TPH2, HRH2, HRH1 EGFR 4129/4885TRPV1 65/4885PIK3CD 3220/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS EGFR 180/4885TRPV1 4703/4885PIK3CD 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.